한글목차

2024년, 주요 16개국에서 푹스각막내피이상증(FECD)의 총 유병자 수는 1억 3,300만 명에 달할 것으로 예상됩니다. 현재 FDA가 승인한 FECD 치료제는 없으며, FECD에 대한 최신 가이드라인은 미국 안과학회에서 작성했습니다.

FECD의 파이프라인은 주로 효소 억제제인 Rho 키나아제2 억제제와 mTOR(포유류 라파마이신 표적) 억제제로 구성되어 있습니다.

FECD를 대상으로 한 전 세계 임상시험의 약 59%가 북미에서 진행되었으며, 유럽이 26.47%, 아시아태평양이 14.7%로 그 뒤를 이었습니다.

지난 10년간 FECD의 개발기업과 관련된 거래는 유럽과 아시아태평양에서 파트너십에 의한 거래가 주류를 이루었습니다.

이 보고서는 전 세계 푹스각막내피이상증(FECD) 시장에 대해 조사했으며, 질환 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 시판약
• 작용기서별 개요
• 투여 경로별 개요
• 시판약 프로파일과 판매량 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지 시간

제6장 파이프라인 약제 평가

• 제III상 파이프라인 약제
• 개발 단계별 개요
• 분자 유형별 개요
• 작용기서별 개요
• 투여 경로별 개요
• 의약품 특이적 상전이 성공률(PTSR)과 승인 가능성(LoA)
• 치료 분야 및 적응증 고유의 PTSR 및 LoA

제7장 임상시험 평가

• 과거 개요
• 단계별 개요
• 상황별 개요
• 진행중 및 계획중인 시험 단계별 개요
• 가상 컴포넌트를 사용한 임상시험
• 지역적 개요
• 지역별 단일국 및 다국적 시험
• 상위 20개사 스폰서와 단계별 내역
• 상위 20개사 스폰서 상황별 내역
• 엔드포인트 상황별 개요
• 인종 및 민족별 개요
• 등록 데이터
• 임상시험 사이트 상위 20개국
• 세계의 상위 20개 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

• 주요 시장 진출 기업

제10장 향후 시장 성장 촉진요인

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in FECD therapeutics.

• More than 133,000,000 total prevalent cases of FECD are expected in 2024 in the 16 countries covered in GlobalData's epidemiology forecast for FECD.
• Currently there are no FDA approved therapies for FECD. The most recent guideline for FECD was developed by the American Academy of Ophthalmology.
• The pipeline for FECD mainly consists of enzyme inhibitors Rho kinase 2 inhibitor and mTOR (mammalian target of rapamycin) inhibitor.
• Around 59% of worldwide trials addressing FECD were conducted in the North America region, followed by Europe with 26.47% of trials and Asia-Pacific with 14.7% of the total trials.
• In deals involving companies developing FECD assets that occurred during past 10 years, partnership emerged as the dominant deal type in Europe and Asia-Pacific.

Scope

GlobalData's FECD: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the FECD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global FECD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Annual Therapy Cost
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer